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Abstract 
Background: Prevention and treatment of  malaria during pregnancy is crucial for reduction of  malaria in pregnancy and its 
adverse outcomes. The spread of  parasite resistance to Sulphadoxine-Pyrimethamine (SP) used for Intermittent Preventive 
Treatment for malaria in pregnancy (IPTp), particularly in East Africa has raised concerns about the usefulness and the reli-
ability of  the IPTp regimen. We aimed to assess the effectiveness of  two doses of  SP in treating and preventing occurrence 
of  adverse pregnancy outcomes. 
Methodology: The study was an analytical cross sectional study which enrolled 350 pregnant women from Kibiti Health 
Centre, South Eastern Tanzania. Structured questionnaires were used to obtain previous obstetrics and medical history of  
participants and verified by reviewing antenatal clinic cards. Maternal placental blood samples for microscopic examination 
of  malaria parasites were collected after delivery. Data was analyzed for associations between SP dosage, risk for PM and 
pregnancy outcome. Sample size was estimated based on precision
Results: Prevalence of  placental maternal (PM) was 8% among pregnant women (95%CI, 4.4-13.1%). Factors associated 
with increased risk of  PM were primigravidity (P<0.001) and history of  fever during pregnancy (P= 0.02). Use of  at least 2 
doses of  SP for IPTp during pregnancy was insignificantly associated with reducing the risk PM (P=0.08), low birth weight 
(P=0.73) and maternal anemia (P=0.71) but associated significantly with reducing the risk of  preterm birth (P<0.001).  
Conclusion: Two doses of  SP for IPTp regime are ineffective in preventing and treating PM and adverse pregnancy out-
come. Hence a review to the current IPTp regimen should be considered with possibility of  integrating it with other malaria 
control strategies. 
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Despite integrated efforts to control malaria in endemic 
areas, PM remains a significant cause of  maternal and 
infant mortality and morbidity. Malaria in pregnancy 
remains a major public health problem especially in 
sub-Saharan African countries where approximately 
25 million pregnant women are at risk of  P. falciparum 
infection every year7. About 25% of  these pregnant 
women have evidence of  placental parasitaemia during 
delivery and have increased risk of  maternal and peri-
natal mortality8. In Tanzania, the prevalence of  PM is 
8% which is lower compared to the overall estimated 
prevalence for Africa19.  
 
Available literature ascertains that, the parity pattern of  
malaria susceptibility in highly endemic areas show that 
primigravidae and secundigravidae (to a lesser extent) 
are more affected than multigravida22. P.falciparum para-
sites are known to invade the placenta in semi-immune 
women to cause PM, a condition associated with still-
birth, spontaneous abortion, fetal pre-maturity, and ma-
ternal anemia15, low birth weight (LBW). Most of  these 
pregnancy outcomes are important risk factors for ne-
onatal mortality and retarded growth regardless of  the 
factors that affect malaria epidemiology in a given lo-
cation5,15,22,23,29. Many studies suggest that, multigravida 
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women have less risk of  PM than primigravida because 
they have developed immunity to sequestered parasites 
10,11. In sub-Saharan Africa, 20% of  LBW has been at-
tributed to malaria in pregnancy20. 
 
Prevention and treatment of  malaria during pregnancy 
is crucial for reduction of  parasitaemia and improving 
birth outcomes. World Health Organization (WHO 
2004) and international Roll BackMalaria (RBM) in-
itiative recommended three cost effective protective 
measures for all pregnant women, which are the use of  
IPTp, insecticide-treated mosquito nets and effective 
case management of  malarial illnesses40. In Tanzania, 
these recommendations are implemented through the 
National Malaria Control Program (NMCP) and up to 
2010, 57% of  all pregnant women in Tanzania slept un-
der an Insecticide Treated bed-Net (ITN) while 60% 
of  them used at least one dose of  IPTp. Sulphadox-
ine-Pyrimethamine (SP) has been widely used for inter-
mittent preventive treatment during pregnancy (IPTp) 
as a means to avoid poor outcomes that are associated 
with PM4. 
 
IPTp using SP is recommended in areas of  high malaria 
transmission with low resistance to SP (World Health 
Organization 2003). In Tanzania, the policy is to offer 
SP to all pregnant women attending antenatal clinics38 
at between 20 and 24 weeks gestation for the first dose 
and between 28 and 32 weeks for the second dose2. 
The newly proposed regimen that requires administra-
tion of  monthly IPTp dose from second trimester un-
til delivery has not yet beeneffectively implemented in 
the country.  It has been documented that, the propor-
tion of  pregnant women receiving single dose of  SP in 
Zambia is about twice (60%) as much as those receiving 
two doses (27%), where single dose proved to be inferi-
or to higher doses14,16.  
 
The changing patterns in malaria epidemiology and 
pathogenesis may imply major shifts in traditional par-
adigms of  associations between placental malaria and 
its risk factors on one hand, and its fetal-maternal out-
comes on the other hand. We aimed at assessing the 
prevalence of  placental malaria in women living in a 
high transmission setting, and to determine the risk 
factors associated with it, including Bednet use and SP 
prophylaxis as IPTp during pregnancy, and the effects 
on pregnancy outcomes. 
 
Methods
Study design and area  
This study was a hospital based descriptive cross sec-
tional study involving pregnant women, conducted be-
tween September and December 2012 in Rufiji district, 
South-Eastern Tanzania. This is an area of  high malaria 
transmission with prevalence of  20.8% (NBS, 2008). It 
lies 500 meters below sea level and receives an annual 
rainfall of  800-1000mm. According to data on malaria 
incidence from health care facilities, malaria is the most 
important public health problem for both adult and 
children in Rufiji District (Goodman et al. 2004). The 
most common occupation in the study area is subsist-
ence farming, with rice, maize and cassava being the 
predominant food crops. Residents of  the study area 
are also involved in subsistence animal husbandry, fish-
ing and small-scale trading. Rufiji has very limited tar-
mac roads, a situation that at times of  long rains isolates 
it from major highways and market centers27,28. Malaria 
transmission in this region, measured by the mean num-
ber of  infected bites per person per year (entomologi-
cal inoculation rate) has been estimated at between 79 
and 1,209 infective bites per person per year, and ma-
laria is the leading cause of  outpatient diagnoses, and a 
high proportion of  reported inpatient deaths. Pregnant 
women who attended Kibiti Health Centre (KHC) for 
delivery were recruited for the study. 
 
Sample size
A minimum sample size of  136 women was estimated 
to provide a power of  80% with 5% precision. A total 
of  350 pregnant women with study’s inclusion crite-
ria were consecutively recruited from KHC which in-
creased both the power and precision. 
 
Data collection
Data was collected using a structured questionnaire by 
interviewing participating mothers in the labor ward. 
This involved mothers who were waiting to enter la-
bor and the ones who are in latent phase of  labor. The 
study’s inclusion criteria were women who delivered in 
the study facility, availability of  a placenta for patho-
logical examination and mothers who agreed to partici-
pate in the study by providing written consent. Women 
with serious delivery complications including severe 
post-partum bleeding, eclampsia and other condition 
that lead to case referral to a tertiary hospital were ex-
cluded. Information regarding biographical, obstetrical 
and medical history of  the participant during pregnan-
cy was recorded. Information on the new born was 
also recorded including infant birth weight. Gestation-
al length was estimated based on the date of  recorded 
last normal menstrual period (LNMP) or fundal height 
examination, when LNMP was unknown. Newborns 
were assessed at delivery. All information of  the partici-
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pant from antenatal clinic card and medical registry was 
careful reviewed by the principal investigator. This in-
formation included history of  SP use, birth weights of  
infants and gravidity as well as the use of  medications 
other than SP. Filling of  all questions in the question-
naire was completed on the day of  interview. Question-
naires completed by study assistants were reviewed in 
an evening roundup meeting to verify completeness and 
reliability of  filled information. To determine placental 
malaria (parasitemia), placental blood samples were col-
lected from the maternal side of  the placenta by making 
an incision about 1.5 cm deep on the central maternal 
side by the pool-biopsy methods34 and hence, about 1 cc 
of  blood sample was collected from a small pool creat-
ed in this incision after squeezing. Collected blood sam-
ples were used to prepare thick and thin blood smears 
on microscopic glass slides. Prepared smears were then 
stained with 5% Giemsa’s stain for 30 minutes, fixed in 
absolute methanol for 5 seconds, dried for >45 min-
utes and examined by two independent microscopists at 
100X magnification guided by standard operating pro-
cedures (SOPs). Up to 100 High power fields (HPFs) 
in cases of  very scanty malaria on a slide may be read 
and number of  parasites counted against the white cells 
counted per HPF is recorded. A slide negative after 100 
HPFs was read by two microscopists and declared neg-
ative. Discrepancy findings were reviewed by a third in-
dependent miscroscopist and results obtained were re-
garded as decisive. Hemoglobin was measured by using 
Abbott Cell-Dyn 3700 Hematology Analyzer in which a 
hemoglobin reading below 10g/dL was considered ane-
mia. In addition a packed cell volume measured by spin-
ning heparinized portion of  the placental blood sample 
(PCV) of  30% was interpreted as anemia. 
 
Primary end points
The primary endpoint of  the study was placenta ma-
laria. Secondary outcomes that were assessed under the 
study include preterm birth, low birth weight and ma-
ternal anaemia. Preterm birth was defined as birth be-
fore 37 weeks of  gestational age. Low birth weight was 
defined as a birth weight below 2500 g, and maternal 
anaemia was defined as haemoglobin level below 11 g/
dl at the time of  labor.
Statistical analysis
Data was analyzed using statistical package for social 
sciences (SPSS) version 18. Numerical variables were 
summarized into percentage. Categorical variables were 
summarized using cross-tabulation to estimate different 
proportion. The primary outcome was the proportion 
of  women with placenta malaria. The bi-variate models 
include IPTp, maternal age, gravidity, history of  fever 
in pregnancy, HIV status and ITNs use as explanato-
ry variables.  Multivariate analyses were performed us-
ing multiple logistic regressions to assess the effects of  
multiple factors on study’s outcome and for controlling 
of  confounders. Differences were considered to be sig-
nificant at a cutoff  point of  p≤0.05. 
 
Ethics
Prior to enrollment, participants were informed on 
the objectives, procedures and benefits of  the study. 
They were assured on anonymity and confidentiality 
throughout the study.  Written consent was obtained 
before the participants were enrolled into the study. 
Approval for this study was obtained from Kilimanjaro 
Christian Medical University College Ethical Commit-
tee (CRERC) on behalf  of  the National Ethical Re-
view Board of  Tanzania and permission to conduct the 
study authorized by District Medical Officer (DMO) of  
Rufiji district.  
 
Results
Table 1 summarizes demographic data of  study partici-
pants. Most (58.9%) of  participants were young women 
aged between 20 and 35 years while those below 20 and 
above 35 years were 29.1% and 12% respectively. About 
two thirds (66.3%) were married or cohabiting while 
33.7% were single (unmarried, divorced or windowed). 
One third (33.1%) of  the participating mothers were 
pregnant for the first time (primigravidae) while 15.4%, 
13.1% and 12% were pregnant for the 2, 3 and 4 times 
respectively. Those with 5th pregnancy and above were 
26.4%, with 2.3% of  these being pregnant for the 10th 
time. Most of  the mothers (63.4%) had primary educa-
tion, whereas only 7.4% had acquired secondary edu-
cation and about one third (29.2%) without any formal 
education. A large proportion of  the mothers (97.7%) 
used ITNs regularly and 52.5% of  them took 2 dos-
es of  SP for IPTp while the rest either took one dose 
(40.6%) or did not take SP at all (6.9%). 
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Table 1 - Socio-demographic and obstetric characteristics (N=350) 
  
Characteristic Group Response % response 
        
Socio-demographic characteristics 
        
Maternal age  <20 yrs 
20 – 35 yrs 

























Obstetrics characteristics  
        






































Abbreviation: IPTp = Intermittent Preventive Treatment for malaria in pregnancy;  
                         ITN = Insecticide Treated bed-Net  
  
  
Factors associated with PM and prevalence of  
pregnancy outcomes 
Among the 350 pregnant women studied, 28 (8%; 95% 
CI: 5.5-11.5%) were found to have be positive for PM, 
while those who gave birth to newborns with low birth 
weight and those with maternal anemia and preterm 
birth were 22 (6.3%; 95% CI: 4.1-9.5%), 160 (59.3%; 
95% CI: 53.1-65.2%) and 26 (7.4%; 95% CI: 5-10.8%) 
respectively. By using logistic regression, gravidity and 
history of  fever during pregnancy were closely associ-
ated with PM whereas maternal age, HIV status and 
ITN use were not.  In terms of  gravidity, multigravida 
were 70% less likely to have PM compared to primi-
gravida (OR=0.3; CI 0.1 – 0.7). Pregnant women who 
had fever during their pregnancy were three times more 
likely to have PM compared to those without history 
of  fever (OR=3.2; CI 1.3 – 8.1). The study also showed 
that, maternal age (OR=1.0; CI 0.4 -1.9) and HIV status 
(OR=1.8; CI 0.3 – 12.2) were neither associated with, 
nor were they risk factors for PM (Table 2).  
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The study found that PM did not significantly predis-
pose pregnant women to deliver babies with low birth 
weight (OR=2.4; CI 0.7 – 8.6). The study also revealed 
that, pregnant women with PM were three times more 
likely to develop maternal anemia (OR=3.4; CI 1.3 – 
10.2) and four times more likely to have preterm birth 
(OR=3.8; CI 1.3 – 11.4) compared to the ones without 
PM (Table 3).
TABLE 3 - Pregnancy outcomes based on status of placenta malaria  










Birth weight  
≥ 2.5 kg    








































GA at birth  




















        
Abbreviations: GA = Gestational age; OR= odds ratio; CI = confidence interval; Hb = Haemoglobin level 
*There were 80 participants with no Hb results 
Number of  IPTp-SP doses as a risk factor for PM
The study showed that, use of  2 doses of  SP during 
pregnancy did not significantly reduce the risk of  de-
veloping PM (OR= 0.5; CI 0.2 – 1.1), low birth weight 
(OR=0.9; 0.3 – 2.1) and maternal anaemia (OR=1.1; CI 
0.7 – 1.8). However, 2 doses of  SP was significantly as-
sociated with reduced risk of  preterm birth to as much 
as ten times when compared to the ones who took sin-
gle dose or none (OR=0.1; CI 0.05 – 0.4) (Table 4)
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 Table 2- Factors associated with placenta malaria 
Characteristics Placenta malaria Crude OR (95%CI) p-value Adjusted OR (95%CI) P-value 
No Yes 
Maternal age 
< 25 years 







































































































Abbreviation: P Malaria = Placenta malaria; OR = Odd ration; ITN = Insecticide Treated bed-Net 
TABLE 4 - Effectiveness of IPTp-SP against placental malaria and adverse pregnancy outcome 




































Birth weight  
2.5kg and above      








































GA age at birth  




















        
Abbreviations: GA = Gestational age; OR= odds ratio; CI = confidence interval; Hb = Haemoglobin level 
*There were 80 participants with no Hb results 
 
Discussion 
Malaria in pregnancy is known to be a major public 
health problem that affects millions of  women in tropi-
cal and subtropical regions. In many parts of  Africa, the 
prevalence of  PM is substantially high to about 25%9, 21 
Our data shows the prevalence of  PM to be 28 (8%) in 
the study site along the coast of  Tanzania. The findings 
are similar to two previous studies that were conducted 
almost 7 years ago in two districts in Morogoro, Central 
Tanzania, areas within share similar malaria transmis-
sion intensity with Rufiji19,25. This may be an important 
concern of  having a constant prevalence of  PM for a 
period of  time despite on-going malaria control inter-
ventions in the country.  
 
We show in our study that primigravida were at higher 
risk of  PM compared to multigravida. It is understood 
from previous studies that primigravida are at a higher 
risk of  PM because of  the absence of  previous exposure 
to P.falciparum and therefore they have not yet devel-
oped protective antibodies that block the adhesion of  
parasitized erythrocytes to chondroitin sulfate A (CSA) 
in the placental intervillous space to promote clearance 
of  parasites6,11. Protective immunity to P. falciparum 
malaria is therefore acquired following prolonged expo-
sure in areas of  endemic parasite transmission. Primi-
gravidity as a risk factor for PM is a consensus among 
many studies that usually find it as an important risk 
factor for PM1,12,31. It is therefore important to prioritize 
malaria control measures among primigravida.  History 
of  fever was found to be a significant predictor of  PM 
in this study. It is most likely in our case that, fever cases 
that were observed could have been secondary to previ-
ous malaria illness and/or PM. However, our study had 
limitations to differentiate between non malarial fever 
and confirmed malarial illness during pregnancy period. 
Fever during pregnancy has also been reported as an 
important predictor of  PM in areas with stable malaria 
transmission35.
 
We found in this study that the odds for women with 
PM to develop maternal anemia and to have preterm 
births were 3 and 4, respectively. Despite the absence of  
statistical significance for PM to predispose pregnant 
women to deliver babies with low birth weights, a weak 
predisposition of  2.4 times risk was seen. It has been 
explained in literatures that, parasitized erythrocytes in 
placenta induce local immunologic responses and com-
plement activation that cause dysregulation of  angio-
genesis that leads to placental function insufficiency, fe-
tal growth restriction and ultimately low birth weight6,36. 
PM in this study was found to predispose significantly 
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pregnant women to maternal anemia (P=0.01) and pre-
term birth (P=0.02) but not low birth weight (P=0.16). 
There is a great extent of  disparity between findings 
from different geographical regions. A study done 
in high malaria transmission areas of  eastern Sudan 
which showed no significant association between PM 
and low birth weight (Adam et al. 2010). Study done 
in Accra Ghana by Ofori showed that, PM was signif-
icantly associated with low birth weight and maternal 
anemia30. In another study done by Bako and colleagues 
in North-Eastern Nigeria where malaria transmission 
is high, PM was significantly associated with low birth 
weight and cord parasitaemia3. Study done in Senegal by 
N’Dao and others showed PM was significantly associ-
ated with low birth weight, preterm birth and perinatal 
mortality 26.   
 
In malaria endemic countries like Tanzania, propor-
tions of  parasitized erythrocytes in pregnant women are 
usually higher in the placenta than in peripheral blood 
18,24,32 and with peripheral blood slides examination as 
the standard diagnostics, the real burden of  malaria in 
pregnancy is almost always underestimated in these ar-
eas. Tanzanian National Malaria Control Program im-
plements administration of  at least two doses of  SP in 
the second and third trimester as a standard regimen for 
controlling malaria in pregnancy. We show in our study 
however that, only half  (52.6%) of  pregnant women 
took the recommended two doses of  SP. A lesser pro-
portion of  40.5% took a single dose whereas 6.9% nev-
er took any SP dose during pregnancy. According to 
reports from the National Bureau of  Standards (NBS) 
and Tanzania Demographic and Health Survey (TDHS) 
in 2010, about one third of  pregnant mothers (32.3%) 
took at least two SP doses as recommended by the na-
tional policy. Our data show a notable increase of  SP 
use for IPTp from 32.3% in 2010 to 52.6% in 2012 
of  pregnant women. All these findings possess a ma-
jor challenge to the newly recommended IPTp regimen 
that requires more than 3 doses of  IPTp to be adminis-
tered in pregnancy.  
 
In order to determine the effectiveness of  SP for IPTp, 
PM was considered the primary indicator since is deter-
mined solely by the presence of  parasites in a non mul-
ti-factorial manner.  However, secondarily, the effec-
tiveness of  SP for IPTp was also determined based on 
occurrence of  adverse pregnancy outcome; low birth 
weight, maternal anemia and preterm birth. We show in 
this study that, pregnant women who took two doses of  
SP were not significantly protected against PM, LBW, 
MA. Preliminary data from previous studies have sug-
gested a continued trend in reduction of  effectiveness 
of  SP for IPTp in many African countries13,37,39. 
 
Our data supports the growing concern over the de-
creasing effectiveness of  the two-dose regimen of  SP 
for IPTp in high malaria transmission regions of  East 
Africa17,33. With a great overlap between malaria and 
HIV incidences, the usefulness of  SP for IPTp is not 
only currently questionable due to its widespread and 
increasing resistance, but also its interaction with HIV 
infections during pregnancy. The continued effective-
ness of  SP in such areas is therefore challenged by two 
parameters that must be addressed together if  IPTp 
programs have to be useful. 
 
With growing resistance of  the parasite to SP, it is im-
portant that the regimen for SP use for IPTp is reviewed. 
Simply increasing the dose to 3 doses and above may 
require careful evaluation especially because SP is cur-
rently resisted by parasite strains isolated almost all over 
Tanzania. SP has been a relatively safe drug for use for 
IPTp, with the advantage of  being taken once at a time 
thus maximizing compliance. The use of  most other 
anti-malarial drugs for IPTp, e.g. ACTs, is challenged by 
their potential safety concern to fetus. At a point when 
the use of  SP for IPTp is thus challenged, an integrat-
ed program that involves the use of  alternative drugs, 
ITNs, IRS, and other strategies could be the most viable 
approach to controlling malaria during pregnancy. 
 
Conclusion
The main result in our study was that, the use of  two 
doses of  SP, among pregnant women in Rufiji in Tan-
zania could not reduce the risk prevalence of  PM as 
assessed by presence of  parasitemia. Furthermore, we 
observed that SP use for IPTp did not have significantly 
direct benefit against PM, LBW, MA, although it was 
protective against pre term birth. Hence special con-
sideration needs to be made when planning for malaria 
protective measures in pregnancy. The current SP reg-
imen should be reviewed to accommodate the effect 
of  increased resistance by parasites by either increasing 
the number of  doses or devising and integrated inter-
ventional program that will include other effective ma-
laria control approaches such as IRS and use of  ITNs. 
Having a small sample size and limited to one study 
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district are important study limitations of  which the 
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